Jeil Pharma Holdings Inc (KRX:002620)
South Korea
· Delayed Price · Currency is KRW 8,560.00
-190.00 (-2.17%)
At close: Jun 27, 2025, 3:30 PM KST
Jeil Pharma Holdings Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 763,719 | 769,968 | 794,714 | 787,256 | 756,633 | 755,330 | Upgrade
|
Other Revenue | 9,315 | 9,855 | 9,329 | 5,708 | 5,935 | 6,667 | Upgrade
|
| 773,034 | 779,822 | 804,043 | 792,965 | 762,568 | 761,997 | Upgrade
| |
Revenue Growth (YoY) | -1.63% | -3.01% | 1.40% | 3.99% | 0.07% | 4.13% | Upgrade
|
Cost of Revenue | 556,901 | 573,301 | 589,459 | 612,482 | 582,061 | 570,757 | Upgrade
|
Gross Profit | 216,133 | 206,521 | 214,584 | 180,483 | 180,507 | 191,239 | Upgrade
|
Selling, General & Admin | 162,250 | 158,410 | 146,364 | 146,465 | 149,808 | 144,028 | Upgrade
|
Research & Development | 37,601 | 38,950 | 46,038 | 41,566 | 39,673 | 24,731 | Upgrade
|
Other Operating Expenses | 20,974 | 20,719 | 1,363 | - | - | - | Upgrade
|
Operating Expenses | 220,475 | 217,702 | 193,664 | 188,031 | 189,482 | 169,236 | Upgrade
|
Operating Income | -4,342 | -11,181 | 20,920 | -7,548 | -8,975 | 22,003 | Upgrade
|
Interest Expense | -8,090 | -8,875 | -10,672 | -5,952 | -3,289 | -3,194 | Upgrade
|
Interest & Investment Income | 2,379 | 2,456 | 4,119 | 508.95 | 256.81 | 179.62 | Upgrade
|
Earnings From Equity Investments | - | - | - | - | 2,516 | 623.76 | Upgrade
|
Currency Exchange Gain (Loss) | 1,922 | 3,019 | -169.48 | 314.8 | 816.09 | -722.45 | Upgrade
|
Other Non Operating Income (Expenses) | -7,565 | -7,435 | -2,492 | 856.19 | -2,864 | 344.45 | Upgrade
|
EBT Excluding Unusual Items | -15,696 | -22,016 | 11,706 | -11,820 | -11,539 | 19,235 | Upgrade
|
Impairment of Goodwill | -44,862 | -44,862 | -28,604 | -78,335 | -17,014 | - | Upgrade
|
Gain (Loss) on Sale of Investments | 6,119 | 5,907 | 2,923 | 7,127 | 20,876 | 16,146 | Upgrade
|
Gain (Loss) on Sale of Assets | 11.22 | 7.97 | 0.53 | 23.98 | 1,930 | 6.69 | Upgrade
|
Asset Writedown | -662.52 | -662.52 | -7.42 | -856.39 | -382 | -4,566 | Upgrade
|
Pretax Income | -55,091 | -61,626 | -13,982 | -83,861 | -6,129 | 30,822 | Upgrade
|
Income Tax Expense | 4,928 | 4,765 | -740.82 | -715.62 | 6,741 | 15,881 | Upgrade
|
Earnings From Continuing Operations | -60,019 | -66,391 | -13,241 | -83,145 | -12,870 | 14,941 | Upgrade
|
Net Income to Company | -60,019 | -66,391 | -13,241 | -83,145 | -12,870 | 14,941 | Upgrade
|
Minority Interest in Earnings | 11,112 | 15,232 | -3,009 | 8,589 | 9,388 | -3,510 | Upgrade
|
Net Income | -48,907 | -51,159 | -16,250 | -74,556 | -3,482 | 11,431 | Upgrade
|
Net Income to Common | -48,907 | -51,159 | -16,250 | -74,556 | -3,482 | 11,431 | Upgrade
|
Shares Outstanding (Basic) | 15 | 15 | 15 | 15 | 15 | 15 | Upgrade
|
Shares Outstanding (Diluted) | 15 | 15 | 15 | 15 | 15 | 15 | Upgrade
|
Shares Change (YoY) | 1.79% | - | - | - | - | - | Upgrade
|
EPS (Basic) | -3157.93 | -3332.61 | -1058.54 | -4856.70 | -226.85 | 744.64 | Upgrade
|
EPS (Diluted) | -3158.31 | -3333.00 | -1059.00 | -4857.00 | -227.00 | 744.64 | Upgrade
|
Free Cash Flow | -11,743 | 202.38 | -10,638 | -32,717 | -10,284 | -33,482 | Upgrade
|
Free Cash Flow Per Share | -758.27 | 13.18 | -692.99 | -2131.27 | -669.95 | -2181.10 | Upgrade
|
Dividend Per Share | 50.000 | 50.000 | 50.000 | 50.000 | 65.000 | 70.000 | Upgrade
|
Dividend Growth | - | - | - | -23.08% | -7.14% | - | Upgrade
|
Gross Margin | 27.96% | 26.48% | 26.69% | 22.76% | 23.67% | 25.10% | Upgrade
|
Operating Margin | -0.56% | -1.43% | 2.60% | -0.95% | -1.18% | 2.89% | Upgrade
|
Profit Margin | -6.33% | -6.56% | -2.02% | -9.40% | -0.46% | 1.50% | Upgrade
|
Free Cash Flow Margin | -1.52% | 0.03% | -1.32% | -4.13% | -1.35% | -4.39% | Upgrade
|
EBITDA | 9,665 | 2,918 | 33,476 | 3,357 | 8.31 | 30,654 | Upgrade
|
EBITDA Margin | 1.25% | 0.37% | 4.16% | 0.42% | 0.00% | 4.02% | Upgrade
|
D&A For EBITDA | 14,007 | 14,099 | 12,556 | 10,905 | 8,983 | 8,651 | Upgrade
|
EBIT | -4,342 | -11,181 | 20,920 | -7,548 | -8,975 | 22,003 | Upgrade
|
EBIT Margin | -0.56% | -1.43% | 2.60% | -0.95% | -1.18% | 2.89% | Upgrade
|
Effective Tax Rate | - | - | - | - | - | 51.52% | Upgrade
|
Advertising Expenses | - | 9,597 | 5,929 | 6,228 | 8,742 | 10,675 | Upgrade
|
Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.